Gilead Sciences Inc. (GILD)
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.
2 Top Picks With Contrarian Potential as Q4 Looms
Subscribers to Chart of the Week received this commentary on Sunday, September 29.
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks, reaching a high of $84, its highest point since January and a few points below its all-time high of $89.
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
Why Gilead Sciences Stock Thrashed the Market Today
Lenacapavir, one of several HIV drugs in Gilead's portfolio, met its key endpoints in a late-stage clinical trial. It did even better than Gilead's classic HIV treatment.
Gilead's HIV-prevention drug cut infections by 96%, boosting stock
Gilead's twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.
Gilead's twice-yearly shot cut HIV infections by 96% in trial
Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The data sets the stage for likely FDA approval of Lenacapavir for HIV prevention.
Gilead Sciences, Inc. (GILD) Baird Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences.
